Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12608000535370
ACTRN12608000535370
Completed
Phase 4

Phase IV study, randomized, placebo-controlled for the evaluation of efficacy and tolerability of arginine aspartate in patients with moderate to severe fatigue

ikkho Zydus0 sites60 target enrollmentOctober 22, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsModerate to severe fatigueOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Moderate to severe fatigue
Sponsor
ikkho Zydus
Enrollment
60
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 22, 2008
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ikkho Zydus

Eligibility Criteria

Inclusion Criteria

  • •Patients between 18 to 70 years old
  • •Informed consent
  • •Rate \= or more than 4 in the Piper Scale

Exclusion Criteria

  • •Organic disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
The cardiovascular, renal and gastrointestinal effects of the gut-hormone based therapies liraglutide and sitagliptiType 2 Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2012-003256-36-NLVU University Medical Center
Completed
Phase 4
A phase IV, randomized, double-blind, placebo-controlled, parallel-group trial to assess the effect of 12-week treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide or dipeptidyl peptidase-4 inhibitor (DPP-4i) sitagliptin on the cardiovascular, renal and gastrointestinal system in insulin-naïve patients with type 2 diabetes (T2DM).Type 2 Diabetes Mellitus10018424
NL-OMON41271Vrije Universiteit Medisch Centrum70
Active, not recruiting
Not Applicable
Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants.Rotavirus gateroenteritisTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2015-001545-81-Outside-EU/EEAGlaxoSmithKline Biologicals684
Recruiting
Phase 4
A phase IV, blinded, randomized controlled trial to compare the effectiveness of low pressure pneumoperitoneum during laparoscopic donor nephrectomy to optimize the quality-of-recovery during the early post-operative phasedonor nephrectomykidney donation1003843010038365
NL-OMON40838niversitair Medisch Centrum Sint Radboud64
Active, not recruiting
Not Applicable
Clinical trial to evaluate the immune response and safety of a combined Tdap vaccine(Boostrix, GSK) and antipapilloma human virus vaccine (Gardasil) vaccine when administered with the meningococcal conjugate ACWY Novartis or placebo.Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10027276Term: Meningococcal meningitisSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2011-000476-34-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.800